
Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE - Free Report) - Analysts at Cantor Fitzgerald issued their FY2026 earnings per share estimates for shares of Ultragenyx Pharmaceutical in a research report issued on Monday, June 9th. Cantor Fitzgerald analyst K. Kluska expects that the biopharmaceutical company will earn ($2.61) per share for the year. Cantor Fitzgerald has a "Overweight" rating and a $118.00 price objective on the stock. The consensus estimate for Ultragenyx Pharmaceutical's current full-year earnings is ($5.18) per share.
Ultragenyx Pharmaceutical (NASDAQ:RARE - Get Free Report) last released its earnings results on Tuesday, May 6th. The biopharmaceutical company reported ($1.57) earnings per share for the quarter, missing analysts' consensus estimates of ($1.54) by ($0.03). Ultragenyx Pharmaceutical had a negative return on equity of 193.80% and a negative net margin of 101.60%. The firm had revenue of $139.29 million for the quarter, compared to analysts' expectations of $145.98 million. During the same quarter in the previous year, the company posted ($2.03) earnings per share. The firm's quarterly revenue was up 28.0% on a year-over-year basis.
Other analysts have also recently issued reports about the company. Canaccord Genuity Group raised their price target on Ultragenyx Pharmaceutical from $121.00 to $136.00 and gave the company a "buy" rating in a research note on Tuesday, February 18th. JPMorgan Chase & Co. boosted their target price on Ultragenyx Pharmaceutical from $104.00 to $117.00 and gave the stock an "overweight" rating in a research note on Thursday, March 27th. William Blair assumed coverage on shares of Ultragenyx Pharmaceutical in a research report on Wednesday, May 28th. They set an "outperform" rating and a $65.00 price objective for the company. Piper Sandler lowered their target price on shares of Ultragenyx Pharmaceutical from $140.00 to $115.00 and set an "overweight" rating for the company in a report on Monday, March 17th. Finally, HC Wainwright reaffirmed a "buy" rating and issued a $95.00 target price on shares of Ultragenyx Pharmaceutical in a research report on Friday, February 14th. One investment analyst has rated the stock with a hold rating and twelve have given a buy rating to the company's stock. According to data from MarketBeat, Ultragenyx Pharmaceutical presently has an average rating of "Moderate Buy" and a consensus price target of $88.77.
Get Our Latest Stock Report on Ultragenyx Pharmaceutical
Ultragenyx Pharmaceutical Price Performance
Shares of Ultragenyx Pharmaceutical stock traded down $1.80 during trading on Tuesday, hitting $37.49. 1,094,008 shares of the stock were exchanged, compared to its average volume of 854,670. The firm's 50-day moving average price is $36.04 and its 200 day moving average price is $40.08. The stock has a market cap of $3.54 billion, a price-to-earnings ratio of -5.91 and a beta of 0.25. Ultragenyx Pharmaceutical has a 12-month low of $29.59 and a 12-month high of $60.37.
Institutional Investors Weigh In On Ultragenyx Pharmaceutical
Hedge funds have recently made changes to their positions in the business. Deep Track Capital LP purchased a new stake in Ultragenyx Pharmaceutical during the 4th quarter valued at approximately $27,493,000. Dark Forest Capital Management LP acquired a new position in shares of Ultragenyx Pharmaceutical in the fourth quarter valued at approximately $459,000. First Light Asset Management LLC raised its stake in shares of Ultragenyx Pharmaceutical by 1.1% during the fourth quarter. First Light Asset Management LLC now owns 763,607 shares of the biopharmaceutical company's stock worth $32,125,000 after purchasing an additional 8,505 shares during the last quarter. Stifel Financial Corp raised its stake in shares of Ultragenyx Pharmaceutical by 13.5% during the fourth quarter. Stifel Financial Corp now owns 23,796 shares of the biopharmaceutical company's stock worth $1,001,000 after purchasing an additional 2,835 shares during the last quarter. Finally, Alyeska Investment Group L.P. lifted its holdings in shares of Ultragenyx Pharmaceutical by 23.1% during the fourth quarter. Alyeska Investment Group L.P. now owns 1,439,740 shares of the biopharmaceutical company's stock worth $60,570,000 after purchasing an additional 269,733 shares during the period. Institutional investors and hedge funds own 97.67% of the company's stock.
About Ultragenyx Pharmaceutical
(
Get Free Report)
Ultragenyx Pharmaceutical Inc, a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Japan, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia.
See Also

Before you consider Ultragenyx Pharmaceutical, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Ultragenyx Pharmaceutical wasn't on the list.
While Ultragenyx Pharmaceutical currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.